President Biden's Mohs surgery highlights the need for equitable access to this effective skin cancer treatment, emphasizing its benefits and ongoing disparities.
Dermatology Times, December 2025 (Vol. 46. No. 12)
Explore the latest advancements in chronic spontaneous urticaria (CSU) therapies, including innovative treatments and patient-centered management strategies.
Dermatology Times highlights 2025's innovations in dermatology, featuring new therapies, expert insights, and a look ahead to 2026 advancements.
Emerging biologic combinations may open a new therapeutic frontier for severe HS that fails to respond to conventional and single-pathway biologics.
Explore real-world psoriasis management insights from Anthony Nuara, MD, PhD, focusing on patient-centered approaches and innovative treatments like tildrakizumab.
Sponsored by Takeda
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
The Weekly Roundup: December 8-12
5
